KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to -$129.0 million.

  • Alnylam Pharmaceuticals' Non Operating Income fell 30623.78% to -$129.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.6 million, marking a year-over-year decrease of 12308.42%. This contributed to the annual value of -$200.5 million for FY2024, which is 3247.48% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Non Operating Income stood at -$129.0 million for Q3 2025, which was down 30623.78% from -$19.2 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Non Operating Income registered a high of $19.0 million during Q1 2021, and its lowest value of -$147.9 million during Q3 2022.
  • Its 5-year average for Non Operating Income is -$53.3 million, with a median of -$44.4 million in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Non Operating Income crashed by 58636.84% in 2022 and then skyrocketed by 7564.89% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Non Operating Income (Quarter) stood at -$65.7 million in 2021, then surged by 72.0% to -$18.4 million in 2022, then fell by 15.62% to -$21.3 million in 2023, then crashed by 317.23% to -$88.8 million in 2024, then crashed by 45.29% to -$129.0 million in 2025.
  • Its Non Operating Income was -$129.0 million in Q3 2025, compared to -$19.2 million in Q2 2025 and -$59.7 million in Q1 2025.